LAUSR

Govindaraj, C., Tan, P., Walker, P., Wei, A., Spencer, A. & Plebanski, M. (2014) Reducing TNF receptor 2 + regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients. Clinical Cancer Research, 20, 724–735. Hideshima, T., Bradner, J.E., Chauhan, D. & Anderson, K.C. (2005) Intracellular protein degradation and its therapeutic implications. Clinical Cancer Research, 11, 8530–8533. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., McMullan, C., Poulaki, V., Fanourakis, G., Schlossman, R., Chauhan, D., Munshi, N.C., Hideshima, T., Richon, V.M., Marks, P.A. & Anderson, K.C. (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood, 101, 4055–4062. Ocio, E.M., Davila, J., Caballero, J.C., Alonso, S., de la Calle, V.G., Garcia-Sanz, R., Gazi, L., Opio, S., Jimenez, M., San-Miguel, J.F. & Mateos, M.V. (2015) Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. Haematologica, 100, e289–e291. Popat, R., Brown, S.R., Flanagan, L., Hall, A., Gregory, W., Kishore, B., Streetly, M., Oakervee, H., Yong, K., Cook, G., Low, E. & Cavenagh, J. (2016) Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Lancet Haematology, 3, e572–e580. Richardson, P.G., Hungria, V.T., Yoon, S.S., Beksac, M., Dimopoulos, M.A., Elghandour, A., Jedrzejczak, W.W., Guenther, A., Nakorn, T.N., Siritanaratkul, N., Schlossman, R.L., Hou, J., Moreau, P., Lonial, S., Lee, J.H., Einsele, H., Sopala, M., Bengoudifa, B.R., Corrado, C., Binlich, F. & San-Miguel, J.F. (2016) Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood, 127, 713–721. San-Miguel, J.F., Hungria, V.T., Yoon, S.S., Beksac, M., Dimopoulos, M.A., Elghandour, A., Jedrzejczak, W.W., Gunther, A., Nakorn, T.N., Siritanaratkul, N., Corradini, P., Chuncharunee, S., Lee, J.J., Schlossman, R.L., Shelekhova, T., Yong, K., Tan, D., Numbenjapon, T., Cavenagh, J.D., Hou, J., LeBlanc, R., Nahi, H., Qiu, L., Salwender, H., Pulini, S., Moreau, P., Warzocha, K., White, D., Blade, J., Chen, W., de la Rubia, J., Gimsing, P., Lonial, S., Kaufman, J.L., Ocio, E.M., Veskovski, L., Sohn, S.K., Wang, M.C., Lee, J.H., Einsele, H., Sopala, M., Corrado, C., Bengoudifa, B.R., Binlich, F. & Richardson, P.G. (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncology, 15, 1195–1206. San-Miguel, J.F., Hungria, V.T., Yoon, S.S., Beksac, M., Dimopoulos, M.A., Elghandour, A., Jedrzejczak, W.W., Gunther, A., Nakorn, T.N., Siritanaratkul, N., Schlossman, R.L., Hou, J., Moreau, P., Lonial, S., Lee, J.H., Einsele, H., Sopala, M., Bengoudifa, B.R., Binlich, F. & Richardson, P.G. (2016) Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematology, 3, e506–e515. Sengsayadeth, S., Malard, F., Savani, B.N., Garderet, L. & Mohty, M. (2017) Posttransplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer Journal, 7, e545. Wolf, J.L., Siegel, D., Goldschmidt, H., Hazell, K., Bourquelot, P.M., Bengoudifa, B.R., Matous, J., Vij, R., de Magalhaes-Silverman, M., Abonour, R., Anderson, K.C. & Lonial, S. (2012) Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leukaemia & Lymphoma, 53, 1820–1823.